Low Dose of Metronomic Cyclophosphamide and Capecitabine in Pretreated HER2-negative Metastatic Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01526512
Recruitment Status : Unknown
Verified February 2012 by yanfei Liu, Fudan University.
Recruitment status was:  Recruiting
First Posted : February 6, 2012
Last Update Posted : February 7, 2012
Information provided by (Responsible Party):
yanfei Liu, Fudan University

Brief Summary:
The purpose of this study is to evaluate the role of low dose metronomic cyclophosphamide and capecitabine in pretreated metastatic breast cancer.

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: metroCX Phase 2

Detailed Description:
Metronomic chemotherapy has been considered as an effective strategy in metastatic breast cancer. This trial is designed to evaluate the role of low dose metronomic cyclophosphamide and capecitabine in pretreated metastatic breast cancer.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 72 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : December 2011
Estimated Primary Completion Date : July 2013
Estimated Study Completion Date : July 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: metroCX
metroCX Cyclophosphamide 50mg PO d1-28; Capecitabine 1500mg PO d1-28; every 28days
Drug: metroCX
cyclophosphamide 50mg PO d1-28 capecitabine 1500mg PO d1-28; every 28days

Primary Outcome Measures :
  1. PFS [ Time Frame: 6 weeks ]

Secondary Outcome Measures :
  1. Biomarker [ Time Frame: 6 weeks ]
    Relationship of serum VEGF level and efficacy

  2. Biomarker [ Time Frame: 6weeks ]
    Relationship of immuno-marker(CD3,CD4,CD8,etc) and efficacy

  3. Biomarker [ Time Frame: 1 time ]
    Relationship of genetics(genetic polymorphisms) and efficacy

  4. Efficacy [ Time Frame: 6 weeks ]
    Overall Response rate

  5. Efficacy [ Time Frame: 6 weeks ]
    Overall Survival

  6. Safety [ Time Frame: 3 weeks ]
    Safety(NCI CTCAE v4.0)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Females with age between 18 and 80 years old
  2. ECOG performance between 0-3
  3. Life expectancy more than 3 months
  4. Histological proven unresectable recurrent or advanced HER2-negative breast cancer
  5. At least one previous therapy regimen (including endocrine therapy) for metastatic breast cancer;suitable for monotherapy (Neoadjuvant or adjuvant docetaxel should be completed at least one year).
  6. At least one measurable disease according to the response evaluation criteria in solid tumor (RECIST1.1)
  7. No anticancer therapy within 4 weeks
  8. Adequate hematologic, hepatic, and renal function,No serious medical history of heart, lung, liver and kidney
  9. Provision of written informed consent prior to any study specific procedures
  10. Previous capecitabine is permitted, however, it should be completed at least 6 months.

Exclusion Criteria:

  1. Pregnant or lactating women (female patients of child-bearing potential must have a negative serum pregnancy test within 14 days of first day of drug dosing, or, if positive, a pregnancy ruled out by ultrasound)
  2. Women of child-bearing potential, unwilling to use adequate contraceptive protection during the course of the study
  3. Treatment with an investigational product within 4 weeks before the first treatment
  4. Symptomatic central nervous system metastases
  5. Other active malignancies (including other hematologic malignancies) or other malignancies, except for cured nonmelanoma skin cancer or cervical intraepithelial neoplasia.
  6. Patient having a history of clinically significant cardiovascular, hepatic, respiratory or renal diseases, clinically significant hematological and endocrinal abnormalities, clinically significant neurological or psychiatric conditions
  7. Uncontrolled serious infection
  8. Patients with bad compliance
  9. Patients lack of Dihydropyrimidine Dehydrogenase(DPD)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01526512

Contact: Leiping Wang, MD +862164175590

China, Shanghai
Fudan University Cancer Center Active, not recruiting
Shanghai, Shanghai, China, 200032
Fudan University Cancer Center Recruiting
Shanghai, Shanghai, China, 200032
Contact: Leiping Wang, MD    +862164175590 ext 8908   
Sponsors and Collaborators
Fudan University
Principal Investigator: Zhonghua Wang, MD Fudan University

Responsible Party: yanfei Liu, Principal investigator, Fudan University Identifier: NCT01526512     History of Changes
Other Study ID Numbers: metroCX
First Posted: February 6, 2012    Key Record Dates
Last Update Posted: February 7, 2012
Last Verified: February 2012

Keywords provided by yanfei Liu, Fudan University:
Metronomic cyclophosphamide
Metronomic capecitabine
HER2-negative breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Antimetabolites, Antineoplastic